LivaNova plans a 2027 obstructive sleep apnea launch after submitting a PMA supplement between the end of this year and first half of next year; management expects OSA margin north of 25% by 2030.
LIVN · LivaNova PLC
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
LivaNova raised revenue guidance by 100 bits and EPS guidance by 10 cents, citing stronger cardiopulmonary and epilepsy execution. It reiterated its $200 million to $400 million OSA revenue target by 2030.
LivaNova reported third-quarter revenue of $393 million, up 10%, and raised 2026 revenue growth guidance to 9% to 10% from 8% to 9%, while lifting adjusted diluted EPS guidance to $4.40 to $4.50.
LivaNova PLC said the FDA granted PMA on March 18, 2026, for the aura6000 System to treat adult patients with moderate to severe OSA who failed, do not tolerate, or are ineligible for first-line therapies.
LivaNova reported third-quarter 2026 revenue of $393.1 million, up 9.9%, and adjusted diluted EPS of $1.23, while raising full-year revenue growth guidance to 9%–10% and adjusted diluted EPS to $4.40–$4.50; adjusted free cash flow guidance remained $140 million–$160 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. LivaNova delivered Q2 2026 revenue of $390.6 million (up 9.8% constant-currency / 10.8% reported) with record adjusted EPS of $1.26, raised full-year 2026 revenue growth outlook to 8%–9% and adjusted EPS to $4.30–$4.40, but lowered adjusted free-cash-flow guidance to $140–$160 million due to higher capex and Thermo Fisher funding.
- + Full-year 2026 revenue guidance raised to 8%–9% (from 7%–8%) constant-currency
- + Cardiopulmonary segment outlook raised to 9.5%–10.5% growth (from 8.5%–9.5%)
- + Epilepsy segment outlook raised to 7%–8% growth (from 6%–7%) on reimbursement and CORE data
- − Full-year 2026 adjusted free-cash-flow guidance lowered to $140–$160 million (from $160–$180 million)
- − Full-year capex raised to $135 million (from $120 million) for capacity expansion and IT
- − OSA PMA supplement timing pushed to between 2H 2026 and 1H 2027 from prior 2H 2026 expectation
- − Adjusted free cash flow of $45.5 million declined modestly YoY on higher capex and working capital
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted free cash flow non-GAAP | $45.5M | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities $66.6M
-$31.6M Purchases of property, plant, and equipment
-$0.2M Dividends received from investments
+$10M Payment of contingent consideration included in cash provided by operating activities
+$0.7M 3T Heater-Cooler litigation payments
= Adjusted free cash flow $45.5M
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LIVN
this stock
LivaNova PLC
|
$5.09B | +50.2% | +10.7% | — | 11.5% |
|
ABT
Abbott Laboratories
|
$186.10B | -14.2% | +5.7% | 40.1 | 1.1% |
|
MDT
Medtronic plc
|
$131.60B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$118.29B | -11.6% | +11.2% | 33.1 | 1.7% |
|
BSX
Boston Scientific Corp
|
$63.33B | -54.2% | +12.5% | 18.5 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 19
LivaNova plans a 2027 obstructive sleep apnea launch after submitting a PMA supplement between the end of this year and first half of next year; management expects OSA margin north of 25% by 2030.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LIVN | -0.2% | +18.3% | +25.1% | +17.1% | +50.2% |
| SPY | -1.7% | -3.5% | -1.4% | -2.1% | +8.5% |
| vs SPY | +1.5% | +21.8% | +26.5% | +19.2% | +41.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.